Related Experiment Videos
[Therapeutic strategy for progressive renal disease].
K Hayashi1, Y Ozawa, H Tokuyama
1Department of Internal Medicine, School of Medicine, Keio University.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 8, 2001
Summary
Renal disease contributes to cardiovascular issues, partly due to increased glomerular pressure. Angiotensin converting enzyme inhibitors and calcium antagonists offer renoprotective benefits, especially when renal failure progresses.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Context:
- Renal disease is a significant risk factor for cardiovascular disease.
- Mechanisms of renal impairment progression are not fully understood.
- Renal glomerular hypertension contributes to renal injury.
Purpose:
- To review the role of renal glomerular hypertension in renal injury.
- To discuss the renoprotective mechanisms of Angiotensin converting enzyme inhibitors (ACE-I) and calcium antagonists.
- To highlight the clinical utility of these agents in managing renal disease and cardiovascular complications.
Summary:
- Renal disease elevates glomerular capillary pressure due to reduced afferent arteriolar tone and increased intrarenal angiotensin II.
- Angiotensin converting enzyme inhibitors (ACE-I) provide antihypertensive and renoprotective effects via efferent arteriolar vasodilation.
- Calcium antagonists show benefits in renal disease, with varying efficacy based on the agent and underlying condition; they are crucial when ACE-I are contraindicated.
Impact:
- Understanding these mechanisms can guide therapeutic strategies for patients with coexisting renal and cardiovascular diseases.
- Highlights the importance of managing glomerular hypertension to prevent renal injury.
- Provides insights into the differential use of ACE-I and calcium antagonists in advanced renal failure.